Stifel Nicolaus analyst Rick Wise has maintained their bullish stance on ATRC stock, giving a Buy rating yesterday.Stay Ahead of the ...

In a report released today, Michael Matson from Needham reiterated a Buy rating on Atricure (ATRC – Research Report), with a price target of ...

AtriCure reported preliminary Q4 revenue results that beat the Wall Street consensus, with expectations for sales to grow ...

Check the time stamp on this data. Updated AI-Generated Signals for Atricure Inc. (ATRC) available here: ATRC.

AtriCure, Inc. (ATRC) has launched the cryoSPHERE MAX cryoablation ... generated positive sentiment among investors, driving ...

AtriCure, Inc. (NASDAQ: ATRC) recently announced the receipt of an expanded indication for the AtriClip in CE-marked countries in Europe. The product is now indicated for use in patients at ...

MASON, Ohio, December 23, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management ...

Shares of ATRC opened at $34.72 on Tuesday. The firm’s 50 day moving average is $30.08 and its 200-day moving average is $25.43. The stock has a market capitalization of $1.69 billion ...

Several analysts have weighed in on ATRC shares. UBS Group boosted their price target on shares of AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...